AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Art, science of developing formulations for vaginal microbicides presented.
2003 JUN 12 - (NewsRx.com & NewsRx.net) -- Getting a false negative because of an incorrect HIV formulation was among the many topics discussed by Gordon Dow at a presentation on vaginal topical microbicide development.
His program was hosted by the National Institute of Allergy and Infectious Diseases (NIAID) in association with the U.S. National Institutes of Health (NIH). Dow's presentation was part of "Microbicides 2003," a 4-day workshop held in March at the Sheraton Four Points in Silver Spring, Maryland, by members of the Alliance for Microbicide Development. Highlights of this forum included recent scientific advancements in topical microbicides for HIV and other STDs; collaboration building among investigators in this field; and identification of future research that is critical to reaching product-development goals.
According to Nurjehan Jivani, project manager II at Dow Pharmaceutical Sciences, Dow's program focused on the importance of formulation. "Having the appropriate ...
- SkinMedica and Dow Pharmaceutical Sciences Enter Partnership to Develop...
- Press release article from: PR Newswire July 8, 2003 700+ words
...SkinMedica, Inc. and Dow Pharmaceutical Sciences, Inc. today announced...terms of the agreement, Dow Pharmaceutical Sciences will be responsible for...the partnership with Dow Pharmaceutical Sciences is strategically important...
- Dow Pharmaceutical Sciences Receives FDA Approval of NDA for Galderma's...
- Press release article from: PR Newswire November 2, 2005 700+ words
...2 /PRNewswire/ -- Dow Pharmaceutical Sciences announced today that...developed by scientists at Dow Pharmaceutical Sciences. Dow also managed full...President and CEO of Dow Pharmaceutical Sciences. "Our unique spray...
- Dow Pharmaceutical Sciences Announces FDA Approval of METROGEL(R)...
- Press release article from: PR Newswire July 6, 2005 700+ words
...6 /PRNewswire/ -- Dow Pharmaceutical Sciences announced today that...patented and developed by Dow Pharmaceutical Sciences and will be marketed...President and CEO of Dow Pharmaceutical Sciences. "Galderma's current...
- SkinMedica and Dow Pharmaceutical Sciences Expand Partnership to Develop...
- Press release article from: PR Newswire April 20, 2005 700+ words
...appearance of skin, and Dow Pharmaceutical Sciences, Inc. (Dow), a topical...this partnership with Dow Pharmaceutical Sciences is strategically important...successful collaboration with Dow Pharmaceutical Sciences, which will contribute...
- Dow Pharmaceutical Sciences Opens Satellite Consulting Office in Burlingame,...
- Press release article from: PR Newswire March 30, 2004 700+ words
...30 /PRNewswire/ -- Dow Pharmaceutical Sciences, a contract pharmaceutical...development laboratories of Dow Pharmaceutical Sciences are located in Petaluma...President and CEO of Dow Pharmaceutical Sciences. Dow Pharmaceutical...
- Dr. David Osborne, VP Product Development at Dow Pharmaceutical Sciences,...
- Press release article from: PR Newswire October 28, 2004 700+ words
...Product Development for Dow Pharmaceutical Sciences, presented "Principles...Delivery laboratory at Dow Pharmaceutical Sciences, a Petaluma, California...formulations. About Dow Pharmaceutical Sciences Dow Pharmaceutical Sciences...
- Kaken Pharmaceutical to licence its antifungal compound KP-103 to Dow...
- News wire article from: Chemical Business Newsbase May 11, 2006 700+ words
...licensing agreement with Dow Pharmaceutical Sciences for KP-103, Kaken...compound. Going forward, Dow Pharmaceutical Sciences will develop the agent...trichophytosis unguium. Dow Pharmaceutical Sciences is a California-based...
- Kaken Pharmaceutical to License Its Antifungal Compound KP-103 to Dow...
- Magazine article from: JCNN News Summaries May 11, 2006 700+ words
...licensing agreement with Dow Pharmaceutical Sciences for KP-103, Kaken...compound. Going forward, Dow Pharmaceutical Sciences will develop the agent...trichophytosis unguium. Dow Pharmaceutical Sciences is a California-based...
- Dow Pharmaceutical Sciences Names David W. Osborne Vice President of Product...
- Press release article from: PR Newswire September 23, 2003 700+ words
...23 /PRNewswire/ -- Dow Pharmaceutical Sciences, Inc., a company specializing...development and skin biology at Dow Pharmaceutical Sciences. (Logo: http...SFTH055LOGO ) David brings to Dow Pharmaceutical Sciences more than 18 years of...
- Dow Pharmaceutical Sciences Appoints Sandra Calman, MD as Director of Clinical...
- Press release article from: PR Newswire November 18, 2004 700+ words
...18 /PRNewswire/ -- Dow Pharmaceutical Sciences, specialists in development...Dr. Calman brings to Dow Pharmaceutical Sciences more than 12 years of...Medical Director for Dow Pharmaceutical Sciences. Dr. Calman holds an...
Source: HighBeam Research, Art, science of developing formulations for vaginal microbicides...